SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…
SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome
SGLT-2 Drugs Cut Stroke Risk After Heart Attack
This meta-analysis evaluated SGLT-2 inhibitors in patients hospitalized for acute coronary syndrome with additional risk factors. The analys…
New research shows that a specific diabetes drug can lower the risk of stroke and heart failure in people recovering from a heart attack.
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
Diabetes Meds Do Not Stop COVID-19
A mini-review of observational studies in patients with type 2 diabetes mellitus found that insulin was linked to worse COVID-19 outcomes, w…
Recent research proves that common diabetes pills do not protect you from getting sick or dying from a virus infection.
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…